Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|
Operating cash flow (Indirect Method) | |||||
Cash from operating activities | 266.95%27B | -58.66%7.36B | -6.94%17.8B | -14.43%19.13B | 22.35B |
Net profit before non-cash adjustment | 3.68%12.82B | -5.86%12.36B | 31.31%13.13B | -18.75%10B | --12.31B |
Total adjustment of non-cash items | 256.68%13.43B | -57.24%3.77B | -1.44%8.81B | -15.06%8.93B | --10.52B |
-Depreciation and amortization | 5.51%11.34B | 10.44%10.75B | 5.92%9.73B | 1.10%9.19B | --9.09B |
-Reversal of impairment losses recognized in profit and loss | 23.90%565M | -35.59%456M | 186.64%708M | -32.14%247M | --364M |
-Share of associates | -95.38%8M | -36.16%173M | 251.95%271M | 108.11%77M | --37M |
-Disposal profit | 72.07%-1.62B | -896.90%-5.78B | -150.52%-580M | 157.46%1.15B | ---2B |
-Other non-cash items | 271.24%3.13B | -38.04%-1.83B | 23.19%-1.33B | -156.97%-1.73B | --3.03B |
Changes in working capital | 108.59%753M | -111.99%-8.77B | -2,254.69%-4.14B | 140.68%192M | ---472M |
-Change in receivables | 85.69%-498M | 31.12%-3.48B | -389.30%-5.05B | -63.40%1.75B | --4.77B |
-Change in inventory | 195.91%5.11B | 54.89%-5.33B | -1,073.70%-11.81B | 544.32%1.21B | ---273M |
-Change in payables | -9,994.87%-3.86B | -99.69%39M | 559.83%12.73B | 44.33%-2.77B | ---4.97B |
Dividends paid (cash flow from operating activities) | |||||
Dividends received (cash flow from operating activities) | |||||
Interest paid (cash flow from operating activities) | -48.62%-1.83B | -131.20%-1.23B | -0.95%-532M | 17.66%-527M | -640M |
Interest received (cash flow from operating activities) | -9.87%1.75B | 33.06%1.94B | -4.21%1.46B | 9.83%1.52B | 1.38B |
Tax refund paid | 9.57%-3.44B | -28.40%-3.8B | 9.81%-2.96B | -1.61%-3.28B | -3.23B |
Other operating cash inflow (outflow) | -1M | 0 | 98.92%-1M | 51.56%-93M | -192M |
Operating cash flow | 450.87%23.48B | -72.96%4.26B | -5.87%15.76B | -14.89%16.74B | --19.67B |
Investing cash flow | |||||
Net PPE purchase and sale | -7.11%-18.34B | 2.22%-17.13B | -34.73%-17.51B | -27.18%-13B | ---10.22B |
Net intangibles purchase and sale | -264.56%-1.04B | -533.33%-285M | 29.69%-45M | 91.73%-64M | ---774M |
Net business purchase and sale | ---2.49B | --0 | ---- | ---- | ---775M |
Net investment product transactions | -69.71%2.87B | 1,653.70%9.47B | -76.91%540M | -80.73%2.34B | --12.14B |
Net changes in other investments | -119.91%-457M | 511.29%2.3B | 78.29%-558M | 76.15%-2.57B | ---10.77B |
Investing cash flow | -244.68%-19.46B | 67.88%-5.65B | -32.21%-17.58B | -27.78%-13.29B | ---10.4B |
Financing cash flow | |||||
Net issuance payments of debt | -36.94%1.95B | 342.67%3.09B | -105.74%-1.28B | 1,789.05%22.21B | ---1.32B |
Net common stock issuance | 99.93%-4M | -15.26%-5.73B | -165,733.33%-4.98B | ---3M | ---- |
Increase or decrease of lease financing | -14.06%-438M | 7.91%-384M | -11.50%-417M | -2.75%-374M | ---364M |
Cash dividends paid | 3.09%-4.77B | 4.24%-4.92B | 2.21%-5.14B | -0.04%-5.26B | ---5.25B |
Net other fund-raising expenses | 505.13%632M | 13.81%-156M | 49.30%-181M | -152.04%-357M | --686M |
Financing cash flow | 67.55%-2.63B | 32.42%-8.1B | -173.90%-11.99B | 359.66%16.22B | ---6.25B |
Net cash flow | |||||
Beginning cash position | -12.41%53.39B | -16.64%60.95B | 35.99%73.12B | 5.51%53.77B | --50.96B |
Current changes in cash | 114.68%1.39B | 31.29%-9.49B | -170.18%-13.8B | 550.89%19.67B | --3.02B |
Effect of exchange rate changes | -34.20%1.26B | 17.42%1.92B | 616.09%1.64B | -48.13%-317M | ---214M |
Cash adjustments other than cash changes | ---1M | ---- | ---- | 0.00%-1M | ---1M |
End cash Position | 4.97%56.04B | -12.41%53.39B | -16.64%60.95B | 35.99%73.12B | --53.77B |
Free cash flow | 125.37%3.47B | -482.26%-13.68B | -165.59%-2.35B | -58.21%3.58B | --8.57B |
Currency Unit | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |